Acne vulgaris is the most common human skin disease, affecting the quality of life of millions worldwide. In spite of numerous research efforts, indisputably curative antiacne agents, which target multiple pathogenetic steps of acne (sebum overproduction, unwanted sebocyte proliferation, inflammation) and, moreover, which possess favourable side effect profiles, is still lacking.
The endocannabinoid system (ECS) regulates multiple physiological processes, including cutaneous cell growth and differentiation.
A preclinical trial, phytocannabinoid CBD was found to acts as a potent “universal” anti-acne agent, possessing a unique “triple anti-acne” profile. Due to the combined lipostatic, antiproliferative, and anti-inflammatory effects, the researchers concluded that CBD has potential as a promising therapeutic agent for the treatment of acne vulgaris.
Reference:
Oláh, A., et al. (2014). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. The Journal of Clinical Investigation, vol. 124, no. 9.
